Blocking the PD-1/PD-L1 pathway (Figure 1) is considered one of the main targets of immunotherapy against cancer, with drugs already approved by the Food and Drug Administration (FDA), such as pembrolizumab, nivolumab, atezolizumab, and cemiplimab24,44-.47 The gene discussed is RPL17; the disease is cancer.